Clinical Trial

Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

Study acronym: OPTIMUS-EPIC
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.
Trial Details
NCT Number NCT07734753
Lead Sponsor Sanofi
Conditions Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Enrollment 4,006 participants
Start Date 2025-07-15
Primary Completion 2026-05-15 (estimated)
Study Completion 2026-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-29